Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ARCT
FechaHoraFuenteTítuloSímboloCompañía
15/11/202307:51IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/11/202315:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/11/202315:01Business WireArcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
25/10/202315:01Business WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
23/10/202315:01Business WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/10/202307:30Business WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/09/202307:30Business WireArcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/09/202307:30Business WireStudy Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 VariantsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/09/202307:30Business WireArcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19NASDAQ:ARCTArcturus Therapeutics Holdings Inc
17/08/202307:30Business WireArcturus Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/08/202308:00Business WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/08/202316:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/08/202315:20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/08/202315:01Business WireArcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/08/202315:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
24/07/202315:01Business WireArcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
30/06/202307:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/06/202315:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
01/06/202307:30Business WireArcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase DeficiencyNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/05/202316:00Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/05/202315:01Business WireArcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/04/202307:30Business WireArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
29/03/202305:04Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/03/202315:01Business WireArcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/03/202307:00Business WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/02/202309:30Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/02/202310:10Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
31/01/202307:30Business WireArcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/01/202305:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/12/202216:28Edgar (US Regulatory)Seperately Filed Delaying Amendment Under Securities Act Rule 473 to Delay Effectiveness of a 1933 Act Registration Statement (del Am)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ARCT

Su Consulta Reciente

Delayed Upgrade Clock